相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
J. Strausz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
Ian Olver
Therapeutics and Clinical Risk Management (2016)
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
Karin Jordan et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
Steven M. Grunberg et al.
LANCET ONCOLOGY (2009)
Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability
Lia Gore et al.
PEDIATRIC BLOOD & CANCER (2009)
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide
Paul J. Hesketh et al.
SUPPORTIVE CARE IN CANCER (2009)
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
Brendan Johnson et al.
SUPPORTIVE CARE IN CANCER (2009)
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
Laurel M. Adams et al.
SUPPORTIVE CARE IN CANCER (2009)
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
Jon D. Herrington et al.
CANCER (2008)
Ibodutant -: Tachykinin NK2 receptor antagonist treatment of irritable bowel syndrome
S. Giuliani et al.
DRUGS OF THE FUTURE (2008)
Giving Permission
Steven M. Grunberg
JOURNAL OF CLINICAL ONCOLOGY (2008)
Across Generations: Cancer Treatment in Developing Countries
Zeba Aziz
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
J. Herrstedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages
Xu Wang et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2008)
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models
Caroline Louis et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2008)
Neurokinin 1 receptor antagonism as a possible therapy for alcoholism
David T. George et al.
SCIENCE (2008)
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant):: Potential therapeutic utility in the treatment of schizophrenia
Lee A. Dawson et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium
Lieven Annemans et al.
SUPPORTIVE CARE IN CANCER (2008)
Tachykinins and their functions in the gastrointestinal tract
Y. Shimizu et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Tachykinin receptors in chronic inflammatory lower airway diseases
Maria Altamura et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans
L. A. Houghton et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2007)
Distribution pattern of tachykinin NK2 receptors in human colon:: Involvement in the regulation of intestinal motility
Nadia Jaafari et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2007)
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma
Johan D. Boot et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Prevention of postoperative nausea and vomiting
Sheila M. Wilhelm et al.
ANNALS OF PHARMACOTHERAPY (2007)
Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition
Gaochao Tian et al.
MOLECULAR PHARMACOLOGY (2007)
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany
Florian Lordick et al.
EUROPEAN JOURNAL OF CANCER (2007)
Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
Susan Moore et al.
VALUE IN HEALTH (2007)
MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist
Cecilia Cialdai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Defensive and pathological functions of the gastrointestinal NK3 receptor
Gareth J. Sanger et al.
VASCULAR PHARMACOLOGY (2006)
Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human
Alessandro Lecci et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2006)
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
MJ Millan
PHARMACOLOGY & THERAPEUTICS (2006)
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting:: effect of gender on treatment response
PJ Hesketh et al.
SUPPORTIVE CARE IN CANCER (2006)
Expression of the neurokinin type 1 receptor in the human colon
H Boutaghou-Cherid et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2006)
The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma
V. Schelfhout et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2006)
Species differences in tachykinin receptor distribution:: Further evidence that the substance P (NK1) receptor predominates in human brain
M Rigby et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2005)
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
J Herrstedt et al.
CANCER (2005)
Adjuvant chemotherapy in completely resected non-small-cell lung cancer (vol 23, pg 3270, 2005)
Pisters
JOURNAL OF CLINICAL ONCOLOGY (2005)
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin -: Analysis of combined data from two Phase III randomized clinical trials
RJ Gralla et al.
CANCER (2005)
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo
T Furmark et al.
BIOLOGICAL PSYCHIATRY (2005)
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
M Depré et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Multicomponent therapeutics for networked systems
CT Keith et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges
G Kronenberg et al.
PHARMACOPSYCHIATRY (2005)
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression
MS Kramer et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Neurokinin antagonists and their potential role in treating depression and other stress disorders
JS Albert
EXPERT OPINION ON THERAPEUTIC PATENTS (2004)
Tachykinins and tachykinin receptors:: Structure and activity relationships
TA Almeida et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients
GF Joos et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and Schizoaffective disorder
HY Meltzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
R de Wit et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of the neurolunin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
JB McCrea et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting - Results from a randomized, double-blind, placebo-controlled trial in Latin America
S Poli-Bigelli et al.
CANCER (2003)
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
RA Blum et al.
CLINICAL THERAPEUTICS (2003)
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
PJ Hesketh et al.
EUROPEAN JOURNAL OF CANCER (2003)
Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: Comparison with NK1 and NK3 binding sites
M Saffroy et al.
NEUROSCIENCE (2003)
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
A Holmes et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors
TL Ripley et al.
NEUROPHARMACOLOGY (2002)
Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist
X Emonds-Alt et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2002)
Peripheral tachykinin receptors as targets for new drugs
R Patacchini et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine
M Lördal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Expression of tachykinin NK2 receptor mRNA in human brain
M Bensaid et al.
NEUROSCIENCE LETTERS (2001)
Responses of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors
JMA Laird et al.
NEUROPHARMACOLOGY (2001)
Role of NK2 receptors in gastric barosensitivity and in experimental ileus in rats
M Toulouse et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2001)
The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma
J Kraan et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2001)
Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study
X Langlois et al.
NEUROPHARMACOLOGY (2001)
Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man
K Reid et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
NK1 (substance P) receptor antagonists -: why are they not analgesic in humans?
R Hill
TRENDS IN PHARMACOLOGICAL SCIENCES (2000)
Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats
M Toulouse et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
FD Tattersall et al.
NEUROPHARMACOLOGY (2000)
分享论文
